Laripront tab. d / resorption No. 20

Release form, composition and packaging

Lozenges 1 tab.

lysozyme hydrochloride 10 mg

dequalinium chloride 250 mcg

10 pieces.

- contour cell packages (2) - cardboard packs.

Clinical and pharmacological group: Antiseptic for local use in ENT practice and dentistry

Pharmaco-therapeutic group: Antiseptic

pharmachologic effect

Lysozyme - a natural enzyme (mucopolysaccharidase), forming a complex with viruses and preventing their penetration into cells, has an antiviral effect.

It has an antimicrobial effect against gram-positive and some gram-negative bacteria by destroying the cell wall of microorganisms.

In addition, lysozyme has anti-inflammatory, hemostatic and mucolytic effects due to the blockade of histamine, inactivation of heparin and the breakdown of mucopolysaccharides.

Dequalinium chloride is an antiseptic, effective against gram-positive and gram-negative microorganisms, as well as fungi.

Possessing the ability to reduce surface tension, it ensures the penetration of active substances into deeper areas of the mucous membrane.

Indications

Infectious and inflammatory diseases of the oral mucosa, pharynx and larynx (gingivitis, periodontitis, stomatitis (including candidiasis, thrush), pharyngitis, laryngitis, tonsillitis)

ARVI prevention

sore throat and hoarseness

before and after surgical interventions in the oral cavity and pharynx (dental surgery, operations on the jaw, maxillary sinuses, tonsils).

ICD-10 codes

Dosage regimen

The drug should be kept in the mouth without chewing or swallowing until it is completely dissolved.

After resorption of the tablet, you should refrain from eating or drinking for 30 minutes.

The recommended dose is 1 tab.

every 2-3 hours

Side effect

In some cases, allergic reactions are possible.

Contraindications for use

Hypersensitivity to drug components.

Application during pregnancy and lactation

During pregnancy and lactation, it is possible to use the drug according to indications.

special instructions

Influence on the ability to drive vehicles and use mechanisms

The drug does not affect the ability to drive vehicles and control mechanisms.

Name ENG

LARYPRONT

Clinical and pharmacological group

Antiseptic for topical use in ENT practice and dentistry

ATX code

Other drugs

Dosage

250mcg + 10mg

Structure

1 lozenge contains lysozyme hydrochloride 10 mg and dequalinium chloride 0.25 mg.

Indications

The drug is prescribed for the prevention or treatment of diseases of the oral cavity, larynx, pharynx:

periodontitis

stomatitis

gingivitis

pharyngitis and laryngitis

chronic and acute tonsillitis

after and before operations in the oral cavity and pharynx.

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 3 years

Contraindications

Taking the drug is contraindicated if the patient is allergic to any of the components of the drug.

INN / Active ingredient

lysozyme hydrochloride, dequalinium chloride

Specifications

Category

Sore throat

Scope of the drug

Ear, Throat, Nose

Release form

Tablet

Manufacturer country

Egypt

Package quantity, pcs

twenty

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

MASK RUS

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Topical anti-inflammatory agent

Anatomical and therapeutic characteristics

R02AA20 Other antiseptics

Dosage form

Lozenges

Dosage (volume) of the substance in the preparation

20 mg, 0.25 mg

Expiration date in days

1095

Package weight, g

40

Mode of application

:

Laripront is taken orally, 30 minutes before meals, 1 table.

(kept in the mouth or under the tongue until completely dissolved) every 2-3 hours

within 30 minutes after taking the pill, you should refrain from eating or drinking.